U.S. Bioscience's NeuTrexin
Executive Summary
Will be available in Canada in about one month after receiving a Notice of Compliance from Canada's Health Protection Board Jan. 4 clearing the methotrexate analog for marketing. NeuTrexin (trimetrexate glucuronate inj.) had joint review by HPB and FDA, receiving FDA approval Dec. 17 as a second-line treatment for Pneumocystis carinii pneumonia ("The Pink Sheet" Dec. 20, 1993, p. 3). The company will be conducting Phase IV studies